Furthermore, we found that PCDHGA9 suppresses EMT through TGF-β/Smad2/3 signaling and inhibits proliferation via interacting with β-catenin to antagonize the canonical Wnt pathway, revealing its role as a novel therapeutic target in GC prevention and treatment. This evidence concerns the gene SMAD2 and gastric cancer.